Synonym
Citroxanthin; MUTATOCHROME;
IUPAC/Chemical Name
4,4,7a-trimethyl-2-((2E,4E,6E,8E,10E,12E,14E,16E)-6,11,15-trimethyl-17-(2,6,6-trimethylcyclohex-1-en-1-yl)heptadeca-2,4,6,8,10,12,14,16-octaen-2-yl)-2,4,5,6,7,7a-hexahydrobenzofuran
InChi Key
GFPJSSAOISEBQL-FZKBJVJCSA-N
InChi Code
1S/C40H56O/c1-30(19-13-20-32(3)24-25-35-33(4)23-15-26-38(35,6)7)17-11-12-18-31(2)21-14-22-34(5)36-29-37-39(8,9)27-16-28-40(37,10)41-36/h11-14,17-22,24-25,29,36H,15-16,23,26-28H2,1-10H3/b12-11+,19-13+,21-14+,25-24+,30-17+,31-18+,32-20+,34-22+
SMILES Code
CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(\C)C2OC3(C)CCCC(C)(C)C3=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
552.89
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Radlović N, Janić D, Sajić S, Janković S, Jesić M, Leković Z, Petrović R. [IPEX syndrome--case report]. Srp Arh Celok Lek. 2008 Sep-Oct;136(9-10):538-41. Serbian. doi: 10.2298/sarh0810538r. PMID: 19069348.
2: Kessler P. Farmakogenetika warfarinu [Pharmacogenetics of warfarin]. Vnitr Lek. 2006 Mar;52 Suppl 1:31-4. Czech. PMID: 16637447.
3: John J, Cama HR. Metabolism and biological activity of citroxanthin (mutatochrome) in rat. Int J Vitam Nutr Res. 1972;42(2):278-84. PMID: 5053853.
4: Samková A, Lejhancová K, Hak J, Lukes A. Venous thromboembolism in adolescents. Acta Medica (Hradec Kralove). 2012;55(2):78-82. doi: 10.14712/18059694.2015.59. PMID: 23101270.
5: Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm. 2009 Nov;6(11 Suppl):S34-43. doi: 10.1016/j.hrthm.2009.07.018. Epub 2009 Sep 1. PMID: 19880072.
6: Kemppainen KK, Kemppainen E, Jacobs HT. The alternative oxidase AOX does not rescue the phenotype of tko25t mutant flies. G3 (Bethesda). 2014 Aug 21;4(10):2013-21. doi: 10.1534/g3.114.013946. PMID: 25147191; PMCID: PMC4199707.
7: GRIDGEMAN NT, HUNTER RF, WILLIAMS NE. The pro-vitamin A activity of mutatochrome. J Chem Soc. 1947 Feb:121. PMID: 20238639.
8: Duitsman PK, Barua AB, Becker B, Olson JA. Effects of epoxycarotenoids, beta- carotene, and retinoic acid on the differentiation and viability of the leukemia cell line NB4 in vitro. Int J Vitam Nutr Res. 1999 Sep;69(5):303-8. doi: 10.1024/0300-9831.69.5.303. PMID: 10526773.
9: Jensen LH, Lindebjerg J, Kølvraa S, Crüger DG. Molecular screening for Lynch syndrome: from bench to bedside. J Clin Oncol. 2009 Dec 1;27(34):e224; author reply e225. doi: 10.1200/JCO.2009.24.6744. Epub 2009 Oct 26. PMID: 19858372.
10: GRIDGEMAN NT, HUNTER RF, WILLIAMS NE. The pro-vitamin-A activity of mutatochrome. J Chem Soc. 1947 Jan:131. PMID: 20291125.
11: Zivković S, Kostov M, Pavlović S, Mijović Z. [Histopathological characteristics and coexpression of p53 and p16(INK4a) proteins in renal cancer]. Vojnosanit Pregl. 2008 Nov;65(11):820-4. Serbian. doi: 10.2298/vsp0811820z. PMID: 19069712.
